An overview of the development of anti-tumor organotin derivatives in selected classes of compounds is presented and discussed. High to very high in vitro activity has been found, sometimes equaling that of doxorubicin. Solubility in water is an important issue, dominating the in vivo testing of compounds with promising in vitro properties. The cytotoxicity of the compounds was increased by the presence of a bulky group, an active substituent or one or more polar substituents. Polar substituents may also improve the water solubility. Although organotin derivatives constitute a separate class of compounds, the comparison with cisplatin is inevitable. Among the observed toxicities, neurotoxicity, known from platinum cytostatics, and gastrointestinal toxicity, typical for many oncology drugs, have been detected. Further research to develop novel, useful organotin anti-tumor compounds should be carried out.
Introduction
Platinum compounds such as cisplatin [1, 2] and carboplatin [3] have found wide application in cancer chemotherapy. Testicular, ovarian and bladder cancer have been treated successfully by combinations containing these drugs. Also small cell lung cancer as well as non small cell lung cancer have been shown responsive to platinum chemotherapy. Also other platinum compounds are under investigation for anti-cancer treatment: e.g. ormaplatin and oxaliplatin [4] . In addition to platinum compounds, derivatives of other metals are being investigated for their anti-tumor properties e.g. titanocene [5] .
The disease oriented strategy of the NCI makes use of a disease oriented primary screen. This screen consists of a panel of 60 different human tumor cell lines [6, 7] . The NCI screen provides a tool for structure-activity relationships, new members of known mechanistic classes can be found and new mechanistic classes can be discovered. In the present work, the NCI approach was followed and use was made of an in vitro primary screen with seven human tumor cell lines, of which five belong to the NCI panel.
The next step is the testing of promising new derivatives in human tumor xenografts in nude mice [8, 9] . In vivo testing is in general more time consuming than in vitro testing. In particular nude mice experiments are rather elaborate due to the nature of the animal and the test and evaluation period. Therefore a murine tumor model was selected. Initially, use was made of the mouse L1210 leukemia [10] , later on, the mouse Colon 26 was chosen [11, 12] . This model was expected to possess a higher predictive value than the L1210. Subsequently the application of human tumor xenografts in nude mice can be considered for further characterization of the new derivatives.
In the present study the results of the in vitro and in vivo testing of organotin compounds will be summarized and discussed. As a reference drug, cisplatin will be used. Organotin compounds may yield new leads for the development of anti-tumor drugs, which display [13] [14] [15] .
In Table I Many organotin compounds have been synthesized in the past years. From these compounds, a selection will be presented. As a first example of structurally interesting compounds, a series of organotin derivatives of 1,2-and 1,7-dicarba-closo-dodecaboranes will be discussed. These novel compounds were prepared from dicarboranyltin dichloride [17, 18] . Another type of active organotin compounds are the triphenyltin derivatives [19] . The in vitro activity of two examples is summarized in Table II1 . [20] [21] [22] [23] [24] [25] and their in vitro antitumor activity assessed. The data of selected compounds have been summarized in Table IV . in order to further explore new structural elements and to improve the solubility of the compounds, novel derivatives containing the dihydroxybenzoate [26] and the perfluorobenzoate [27] moieties were prepared. These compounds were tested in vitro and found to display promising activity. Some selected results are summarized in Table V.   Table V 120  85  58  130  130  110  65  130  90  51  50  50  500  120  190  280  115  60  65  100  214  53  86  76  275  60  114  105  145  20  36  50  234  41  66  135 The introduction of a polar group leads to some improvement in the solubility and definitely to considerable in vitro activity. Four of the compounds were tested in vivo in the murine Co 26 model [28] . A summary of the results is given in Table VI . Only compound 34 showed modest activity. Toxicity was mainly gastrointestinal. %  %  27  6  qd7x2  87  100  31  5  single  63  111  5  qd7x2  60  97  33  10  qd7x2  120  97  34  16d7x2   63  126 Based on earlier work, selected organotin steroidcarboxylates have been synthesized [29] . The new compounds 36-42 have been tested in vitro and the results are summarized in Table VII . EVSA-T  WIDR  IGROV M19 MEL   A498  H226  36  18  <3  36  18  51  42  61  37  160  60  390  160  120  220  420  38  409  171  629  150  481  972  1229  39  18  <3  15  17  32  53  53  40  11  <3  22  16  22  11  50  41  16  <3  19  18  51  65  61  42  16  <3  15  <3  51  138  76 The compounds 36-42 displayed appreciable in vitro anti-tumor activity. Compounds 36 and 37 were also studied in vivo in the murine Co 26 tumor model. The compounds appeared to be so toxic in the tumor bearing mice that a second injection could not be given. The toxicity was higly variable due to the poor solubility of the compounds, which were administered as a dispersion in arachidis oil. The solubility of compound 36 in DMSO was poor, that of compound 37 good. After administration qd7xl at a dose of 15 mg/kg compound 36 gave a T/C of 42% and an ILS of 8%, compound 37 gave a T/C of 77% and an ILS of 30%.
Compound 36 thus showed activity in the Colon 26 in mice.
The tin steroidcarboxylates appeared to possess considerable in vitro anti-tumor activity, but solubility still remained a drawback, which affected their in vivo properties. In order to make this type of compounds more soluble, another structure, which contained again a five ring moiety, but now also polar substituents, was designed. This led to the synthesis of organotin terebates [30] . The in vitro test results of three compounds have been summarized in Table VIII . Some compounds such as the organotin terebates merit more detailed investigation.
Further chemical and pharmacological studies are necessary to unravel a structure-activity relationship from which novel organotin anti-tumor drugs for use in patients can be developed.
